共 30 条
- [3] Cancer Statistics in China, 2015 [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) : 115 - 132
- [8] Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS) [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) : 2866 - 2874